CYP2C19 Pharmacogenomic Testing

Why Genotyping Changes Outcomes

Understanding the genetic factors in Clopidogrel activation.

Pro-drug Activation

Clopidogrel requires activation by the CYP2C19 enzyme. Loss-of-function alleles can reduce active metabolite exposure 5 to 10-fold.

Clinical Risk

Intermediate & Poor Metabolizers (IM/PM) have significantly higher rates of stent thrombosis and major adverse cardiovascular events (MACE).

Recent Meta-analysis

Genotype-guided therapy lowered MACE by 30% in IM/PM patients compared to standard clopidogrel treatment.

Who Should Be Tested?

Identifying ideal candidates for pharmacogenomic testing.

ACS or PCI Patients

Highest evidence and benefit for genotype-guided therapy.

History of Stent Thrombosis

May indicate a possible loss-of-function (LOF) allele carrier.

Stroke / TIA Patients

Genotype affects the risk of recurrence on clopidogrel monotherapy.

East-Asian Ancestry

Nearly half of this population are IM or PM, where LOF alleles are common.

High Bleeding Risk

Genotype info helps balance efficacy vs. bleeding risk with potent alternatives.

Your Journey with Genolife Services

A streamlined process for personalized antiplatelet therapy.

Pre-test Counselling

Discuss benefits, limits, inheritance, and alternative antiplatelet options.

Sample Collection

Conveniently provide a 3 mL EDTA blood sample or use a saliva kit.

Expert Interpretation

Reviewed by a team including a Clinical Geneticist, Pharmacologist & Interventional Cardiologist.

Post test

Offered for relatives with CAD who may also need antiplatelet therapy.

References